Details
Stereochemistry | ABSOLUTE |
Molecular Formula | C10H16N3O6S.Na |
Molecular Weight | 329.305 |
Optical Activity | UNSPECIFIED |
Defined Stereocenters | 2 / 2 |
E/Z Centers | 0 |
Charge | 0 |
SHOW SMILES / InChI
SMILES
[Na+].N[C@@H](CCC(=O)N[C@@H](CS)C(=O)NCC(O)=O)C([O-])=O
InChI
InChIKey=QWXDICNEPRTOLR-GEMLJDPKSA-M
InChI=1S/C10H17N3O6S.Na/c11-5(10(18)19)1-2-7(14)13-6(4-20)9(17)12-3-8(15)16;/h5-6,20H,1-4,11H2,(H,12,17)(H,13,14)(H,15,16)(H,18,19);/q;+1/p-1/t5-,6-;/m0./s1
Molecular Formula | Na |
Molecular Weight | 22.9898 |
Charge | 1 |
Count |
|
Stereochemistry | ACHIRAL |
Additional Stereochemistry | No |
Defined Stereocenters | 0 / 0 |
E/Z Centers | 0 |
Optical Activity | NONE |
Molecular Formula | C10H16N3O6S |
Molecular Weight | 306.316 |
Charge | -1 |
Count |
|
Stereochemistry | ABSOLUTE |
Additional Stereochemistry | No |
Defined Stereocenters | 2 / 2 |
E/Z Centers | 0 |
Optical Activity | UNSPECIFIED |
DescriptionCurator's Comment: description was created based on several sources, including
https://www.ncbi.nlm.nih.gov/pubmed/23036594 |
https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=3ef475c9-7938-4870-b336-fb0c2dafb3cd | https://clinicaltrials.gov/ct2/show/NCT01450267
Curator's Comment: description was created based on several sources, including
https://www.ncbi.nlm.nih.gov/pubmed/23036594 |
https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=3ef475c9-7938-4870-b336-fb0c2dafb3cd | https://clinicaltrials.gov/ct2/show/NCT01450267
Glutathione (GSH, also called as reduced glutathione) is a tripeptide with many roles in cells. It conjugates to drugs to make them more soluble for excretion, is a cofactor for some enzymes such as, glutathione reductase, glutathione peroxidases, peroxiredoxins. Glutathione S-transferases catalyse the conjugation of GSH via a sulfhydryl group to electrophilic centers on a wide variety of substrates in order to make the compounds more water-soluble. As a part of homeopathic product, glutathione is used for temporary relief of symptoms related to Free Radical Toxicity including tingling in hands and feet, mood changes, frequent colds, poor digestion, fatigue, and constipation. In addition, for temporary relief of pain in the back from urinating, constant urging and frequent urination, kidneys sensitive to pressure, and pain from back extending down the thigh. Glutathione is an important nutrient for brain function and loss of glutathione has been implicated in Parkinson's disease. In phase II of the clinical trial was investigated whether administration of either dose of glutathione, as a nasal spray, improves PD symptoms over time in a population of individuals with Parkinson's disease (PD). In addition in phase II of clinical trial was shown, that reduced glutathione, an ingredient of RayGel™, has been helpful in decreasing some radiation therapy side effects to the skin. Reduced glutathione plays a vital role in both making DNA and cell repair. Cystic fibrosis (CF) is the most common inherited disease among the Caucasian population with considerable morbidity and reduced life expectancy. Glutathione (GSH) represents the first-line defence of the lung against oxidative stress-induced cell injury. Therapeutic approaches with inhaled GSH could improve the reduced lung antioxidant capacity in order to counterbalance the oxidant stress linked to the chronic airway inflammation and bacterial infection.
CNS Activity
Originator
Approval Year
Targets
Primary Target | Pharmacology | Condition | Potency |
---|---|---|---|
Target ID: Glutathione S-transferases Sources: https://www.ncbi.nlm.nih.gov/pubmed/4436301 |
|||
Target ID: P00390 Gene ID: 2936.0 Gene Symbol: GSR Target Organism: Homo sapiens (Human) Sources: https://www.ncbi.nlm.nih.gov/pubmed/23036594 |
|||
Target ID: Glutathione peroxidases Sources: https://www.ncbi.nlm.nih.gov/pubmed/23036594 |
Conditions
Condition | Modality | Targets | Highest Phase | Product |
---|---|---|---|---|
Palliative | Unknown Approved UseUnknown |
|||
Palliative | Unknown Approved UseUnknown |
|||
Primary | Unknown Approved UseUnknown |
|||
Palliative | Unknown Approved UseUnknown |
|||
Primary | Unknown Approved UseUnknown |
PubMed
Title | Date | PubMed |
---|---|---|
Elevation of glutathione level in rat hepatocytes by hepatocyte growth factor via induction of gamma-glutamylcysteine synthetase. | 1999 Nov |
|
Stimulation of p38 mitogen-activated protein kinase is an early regulatory event for the cadmium-induced apoptosis in human promonocytic cells. | 2000 Apr 14 |
|
Synergistic effect of diesel organic extracts and allergen Der p 1 on the release of chemokines by peripheral blood mononuclear cells from allergic subjects: involvement of the map kinase pathway. | 2000 Aug |
|
A rice functional transcriptional activator, RISBZ1, responsible for endosperm-specific expression of storage protein genes through GCN4 motif. | 2001 Apr 27 |
|
Major changes in human ocular UV protection with age. | 2001 Jan |
|
Dose response of carboplatin-induced hearing loss in rats: antioxidant defense system. | 2001 Jan |
|
Overcoming drug resistance in ovarian carcinoma. | 2001 Jan |
|
Glutathione in induced sputum of healthy individuals and patients with asthma. | 2001 Jan |
|
Tamoxifen mutagenesis and carcinogenesis in livers of lambda/lacI transgenic rats: selective influence of phenobarbital promotion. | 2001 Jan 10 |
|
Affinity labeling of rat glutathione S-transferase isozyme 1-1 by 17beta -iodoacetoxy-estradiol-3-sulfate. | 2001 Jan 19 |
|
Role of multidrug resistance protein 1 (MRP1) and glutathione S-transferase A1-1 in alkylating agent resistance. Kinetics of glutathione conjugate formation and efflux govern differential cellular sensitivity to chlorambucil versus melphalan toxicity. | 2001 Mar 16 |
|
Characterization of transsulfuration and cysteine biosynthetic pathways in the protozoan hemoflagellate, Trypanosoma cruzi. Isolation and molecular characterization of cystathionine beta-synthase and serine acetyltransferase from Trypanosoma. | 2001 Mar 2 |
|
Enhanced multispecificity of arabidopsis vacuolar multidrug resistance-associated protein-type ATP-binding cassette transporter, AtMRP2. | 2001 Mar 23 |
|
Silencing mediator for retinoid and thyroid hormone receptors interacts with octamer transcription factor-1 and acts as a transcriptional repressor. | 2001 Mar 30 |
|
Carbon dioxide stimulates the production of thiyl, sulfinyl, and disulfide radical anion from thiol oxidation by peroxynitrite. | 2001 Mar 30 |
|
A direct inhibitory role for the Rab3-specific effector, Noc2, in Ca2+-regulated exocytosis in neuroendocrine cells. | 2001 Mar 30 |
|
Protein kinase C activation modulates alpha-calmodulin kinase II binding to NR2A subunit of N-methyl-D-aspartate receptor complex. | 2001 Mar 9 |
|
Different metabolizing ability of thiol reactants in human and rat blood: biochemical and pharmacological implications. | 2001 Mar 9 |
Patents
Sample Use Guides
For temporary relief of symptoms related to Free Radical Toxicity: 1-10 drops under the tongue, 3 times a day or as directed by a health professional. Consult a physician for use in children under 12 years of age.
pain in the back from urinating: 10 drops orally, 3 times a day. Consult a physician for use in children under 12 years of age.
Breast Cancer: RayGel Topical Cream applied in thin layer to the area exposed to radiation 60-90 minutes prior to radiotherapy, standard skin care between treatments.
Cystic Fibrosis: Inhaled Reduced Glutathione 10 mg/kg, twice daily, 12 months
Route of Administration:
Other
Substance Class |
Chemical
Created
by
admin
on
Edited
Sat Dec 17 15:02:26 UTC 2022
by
admin
on
Sat Dec 17 15:02:26 UTC 2022
|
Record UNII |
H0X6UKX533
|
Record Status |
Validated (UNII)
|
Record Version |
|
-
Download
Name | Type | Language | ||
---|---|---|---|---|
|
Systematic Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English |
Code System | Code | Type | Description | ||
---|---|---|---|---|---|
|
H0X6UKX533
Created by
admin on Sat Dec 17 15:02:26 UTC 2022 , Edited by admin on Sat Dec 17 15:02:26 UTC 2022
|
PRIMARY | |||
|
SUB76116
Created by
admin on Sat Dec 17 15:02:26 UTC 2022 , Edited by admin on Sat Dec 17 15:02:26 UTC 2022
|
ALTERNATIVE | |||
|
SUB13991MIG
Created by
admin on Sat Dec 17 15:02:26 UTC 2022 , Edited by admin on Sat Dec 17 15:02:26 UTC 2022
|
PRIMARY | |||
|
92043348
Created by
admin on Sat Dec 17 15:02:26 UTC 2022 , Edited by admin on Sat Dec 17 15:02:26 UTC 2022
|
PRIMARY | |||
|
DTXSID90955757
Created by
admin on Sat Dec 17 15:02:26 UTC 2022 , Edited by admin on Sat Dec 17 15:02:26 UTC 2022
|
PRIMARY | |||
|
34212-83-4
Created by
admin on Sat Dec 17 15:02:26 UTC 2022 , Edited by admin on Sat Dec 17 15:02:26 UTC 2022
|
NON-SPECIFIC STOICHIOMETRY | |||
|
20167-21-9
Created by
admin on Sat Dec 17 15:02:26 UTC 2022 , Edited by admin on Sat Dec 17 15:02:26 UTC 2022
|
PRIMARY | |||
|
251-884-1
Created by
admin on Sat Dec 17 15:02:26 UTC 2022 , Edited by admin on Sat Dec 17 15:02:26 UTC 2022
|
PRIMARY |
Related Record | Type | Details | ||
---|---|---|---|---|
|
PARENT -> SALT/SOLVATE |
Related Record | Type | Details | ||
---|---|---|---|---|
|
ACTIVE MOIETY |